Stockscreener 앱 받기
81.93
1.87%
-1.56
시간 외 거래:
81.93
전일 마감가:
$83.49
열려 있는:
$84.07
하루 거래량:
352.50K
Relative Volume:
0.41
시가총액:
$5.12B
수익:
$209.22M
순이익/손실:
$45.91M
주가수익비율:
129.37
EPS:
0.6333
순현금흐름:
$63.71M
1주 성능:
+1.56%
1개월 성능:
+2.09%
6개월 성능:
+50.25%
1년 성능:
+118.95%
1일 변동 폭
$81.56
$84.72
1주일 범위
$80.99
$85.05
52주 변동 폭
$33.70
$96.54
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
명칭
Protagonist Therapeutics Inc
전화
(510) 474-0170
주소
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
81.93 | 5.22B | 209.22M | 45.91M | 63.71M | 0.6333 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-12 | 개시 | Leerink Partners | Outperform |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-12-06 | 개시 | Goldman | Neutral |
| 2024-11-05 | 개시 | Wedbush | Outperform |
| 2024-09-24 | 개시 | TD Cowen | Buy |
| 2024-09-09 | 개시 | Truist | Buy |
| 2023-10-30 | 개시 | CapitalOne | Overweight |
| 2023-05-25 | 재개 | Jefferies | Buy |
| 2022-08-25 | 개시 | JMP Securities | Mkt Outperform |
| 2022-02-11 | 개시 | BTIG Research | Buy |
| 2021-10-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-11 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-05-24 | 개시 | JMP Securities | Mkt Outperform |
| 2021-05-24 | 개시 | Northland Capital | Outperform |
| 2021-01-06 | 개시 | JP Morgan | Overweight |
| 2020-12-16 | 개시 | Piper Sandler | Overweight |
| 2020-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-15 | 개시 | Jefferies | Buy |
| 2020-05-18 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-08 | 개시 | H.C. Wainwright | Buy |
| 2019-05-09 | 업그레이드 | Stifel | Hold → Buy |
| 2018-12-06 | 개시 | Nomura | Buy |
| 2018-01-29 | 개시 | Stifel | Buy |
| 2017-07-21 | 개시 | BTIG Research | Buy |
모두보기
Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스
H.C. Wainwright Raises Protagonist Therapeutics, Inc. (PTGX) Target to $117, Reiterates Buy - Finviz
10 Best Long Term Healthcare Stocks to Buy - Insider Monkey
Protagonist Therapeutics director sells $1.67 million in shares By Investing.com - Investing.com Canada
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Director Sells 20,000 Shares of Stock - MarketBeat
Assessing Protagonist Therapeutics (PTGX) Valuation After Rusfertide NDA Filing And Rising Analyst Optimism - simplywall.st
Precision Trading with Protagonist Therapeutics Inc. (PTGX) Risk Zones - Stock Traders Daily
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 - El Paso Times
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: A Biotech Gem with 22% Upside Potential - DirectorsTalk Interviews
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress - The Asheville Citizen Times
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $118.00 at Jefferies Financial Group - MarketBeat
Jefferies Raises Price Target for PTGX to $118, Maintains 'Buy' Rating | PTGX Stock News - GuruFocus
ClearBridge small-cap growth trims Duolingo, Biohaven, QLYS; adds PTGX, SSD, BETA, DYN in Q4 - MSN
Equities Analysts Set Expectations for PTGX FY2030 Earnings - MarketBeat
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes - AOL.com
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Unicycive Therapeutics (UNCY) - The Globe and Mail
PTGX: HC Wainwright & Co. Raises Price Target and Maintains Buy Rating | PTGX Stock News - GuruFocus
Breaking Down Protagonist Therapeutics: 8 Analysts Share Their Views - Benzinga
Protagonist Therapeutics stock price target raised to $117 from $80 at H.C. Wainwright - Investing.com Canada
Protagonist Therapeutics CMO Sells Shares in Major Transaction - Intellectia AI
Protagonist Therapeutics, Inc. $PTGX Shares Sold by Great Lakes Advisors LLC - MarketBeat
Protagonist Therapeutics: Assessing The 2026 Upside For Icotrokinra And Rusfertide - Seeking Alpha
Protagonist Therapeutics CEO Patel sells $4m in shares By Investing.com - Investing.com South Africa
Ali Asif, CFO of protagonist, sells $3.8m in PTGX stock - Investing.com Canada
PTGX SEC FilingsProtagonist Ther 10-K, 10-Q, 8-K Forms - Stock Titan
Protagonist Therapeutics CEO Patel sells $4m in shares - Investing.com
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Insider Sells 5,000 Shares of Stock - MarketBeat
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Insider Sells 13,151 Shares of Stock - MarketBeat
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells 24,890 Shares of Stock - MarketBeat
Protagonist Therapeutics chief medical officer sells $1.9m in shares By Investing.com - Investing.com Canada
JPMorgan reiterates Overweight rating on Protagonist Therapeutics stock By Investing.com - Investing.com Canada
VIX Spike: Can Protagonist Therapeutics Inc weather a recessionStop Loss & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Universal Beteiligungs und Servicegesellschaft mbH Raises Stock Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) CFO Asif Ali Sells 46,203 Shares - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Technical Reactions to PTGX Trends in Macro Strategies - Stock Traders Daily
Have Insiders Sold Protagonist Therapeutics Shares Recently? - Sahm
Earnings Risk: Will Protagonist Therapeutics Inc benefit from AI trendsAnalyst Downgrade & Daily Market Momentum Tracking - baoquankhu1.vn
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - citizen-times.com
Analysts Are Bullish on These Healthcare Stocks: Protagonist Therapeutics (PTGX), CG Oncology, Inc. (CGON) - The Globe and Mail
Protagonist therapeutics CEO Patel sells $2.84 million in shares By Investing.com - Investing.com India
Protagonist therapeutics CMO Molina sells $784k in shares By Investing.com - Investing.com Canada
Asif Ali Sells 8,588 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Insider Arturo Md Molina Sells 9,514 Shares - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $2,840,446.24 in Stock - MarketBeat
Protagonist therapeutics CEO Patel sells $2.84 million in shares - Investing.com
Protagonist Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Strong Buy Ratings Signal Potential 17% Upside - DirectorsTalk Interviews
US Market Wrap: Is Protagonist Therapeutics Inc trading at a discount2025 Bull vs Bear & Free Community Consensus Stock Picks - baoquankhu1.vn
Protagonist Therapeutics Inc (PTGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Protagonist Therapeutics Inc 주식 (PTGX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Waddill William D. | Director |
Feb 06 '26 |
Sale |
83.68 |
20,000 |
1,673,600 |
7,825 |
1.24%
0.19%
자본화:
|
볼륨(24시간):